



Sino-American Pharmaceutical Professionals Association - Greater Philadelphia  
**SAPA-GP**



**Career Development Forum  
& 2011 Chinese New Year's Party**

**大费城美中医药协会  
职场事业发展研讨会及 2011 新春晚会**

**Saturday, February 5, 2011  
1:30 – 10:00 PM**

**Holiday Inn & Conference Center, Fort Washington, PA  
432 W Pennsylvania Ave, Fort Washington, PA 19034  
215-643-3000, www.fwholiday.com**

**Registration is available online at <http://www.sapa-gp.org/workshop/regb.php>**

**Event Partners**

**费城华人计算机协会, 北大校友会, 北医大校友会, 华人专业协会,  
费城三校 (Penn, Temple, Drexel) 学生学者联谊会**

\*\*\*\*\*

大费城美中医药协会 (SAPA-GP) 联合费城华人计算机协会, 北大校友会, 北医大校友会, 费城三校 (Penn, Temple, Drexel) 学生学者联谊会, 华人专业协会 将于 2 月 5 日下午 2 点至晚上 10 点在宾州 Fort Washington 的 Holiday Inn 举办职场事业发展研讨会及 2011 中国新年聚会。多名来自美国和中国著名药企的总裁级要员将介绍当今化学和生物制药业的职业与就业的趋向与机遇, 并将和与会者们讨论业界内专业人士的职业生涯发展与开拓。

Career Development Forum includes speakers and panelists who will share their view on career opportunities and development for professionals working in the biopharm industry, and provides a unique opportunity for participants to learn from and interact with top executives from U.S. and Chinese pharmaceutical and biotech companies with this regard. The workshop will be followed by 2011 Chinese New Year's Party, to celebrate the culture heritage shared by Chinese Communities.

## 1:30 – 5:30 pm Career Development Forum

Moderators: Joan Shen, MD, PhD & Sean Zhang, MD

- 1:30 – 2:00      **Checking-In and Networking**
- 2:00 – 2:10      **Opening Remarks**  
Jingsong Wang, MD  
SAPA-GP President
- 2:10 – 2:40      **Keynote Speech**  
**Chinese Pharma Industry R&D, and My Personal Experience and Views**  
Peng Wang, PhD  
Chief Science Officer, Simcere Pharmaceutical Group, Nanjing, China
- 2:40-3:00      **Finding the Right Fit: Biotech , CRO and Pharma, My Experience in Beijing, China**  
Chang Bai, PhD  
VP, Biology, Pharmaron, Inc.
- 3:00-3:20      **Leverage Your Expertise, Transform Challenges into Actionable Opportunities**  
Wenyong Wang, Ph.D  
Vice President, Investment Banking, Boenning & Scattergood, Inc.
- 3:20-3:40      **Opportunities and Challenges of Working in China – My Personal Experience**  
Marlon Zhong, PhD  
President of PharmaAdvance, Inc.
- 3:40-4:00      **Entrepreneurship within the Organization**  
Lee Kang, PhD, MBA  
Director, Asia Pacific Quality Operations, Perrigo Company

*4:00 – 4:20 Break*

- 4: 20-5:30      **Career Forum Panel Discussion**  
**Co-Chairs:**  
Ruiping Dong, MD, PhD, SVP, Head of Emerging Market R&D, Merck, Co.  
Jingsong Wang, MD, President, SAPA-GP
- Panelists:**  
**All the speakers plus**  
Charles Huang, VP, Business Development, Sundia MediTech  
Robert Huang, PhD, MBA, President, Abgent, Inc  
Jason Jin, MD, PhD, CEO, ShanghaiBio  
Song Li, PhD, President & CEO, Frontage Laboratories  
Peter Luo, PhD, Founder & Chairman, Adagene  
Steve Sun, PhD, President, GeneWiz  
Patrick Wong, PhD, Director, Consultant Group, Qin Huang Dao Nobel Bio-

Medical Industrial Park, Hebei, China

[Lianshan Zhang, PhD](#), President of Global R&D, Jiangsu Hengrui Medicine

**Topics of panel discussion will include but not limited to:**

- What do the new global market and job migration tell us?
- Where are those exciting career opportunities?
- What are those factors influencing career decisions for Chinese professionals working in the biopharm industry?
- What are the potential hurdles for career changes and career advancement?
- How should one prepare for the future (job opportunities or changes)?

**5:30-6:30pm**      **Dinner Reception**

**6:30-10:00pm**      **Chinese New Year Party**

- Free of Charge
- Dress code: Business Casual
- Traditional Chinese Costume is Encouraged

6:30-7:00pm      1. Potential Employer Profile (Abgent, Sundia, QHD Park, Frontage)  
2. SAPA-GP President New Year Address

7:00-7:30pm      **Performance by Melody Dance Group 旋律艺术团 and SAPA-GP Member/Family**


1. 儿童表演 新年好  
Happy New Year
2. 舞蹈 花儿为什么这样红  
Why flowers are so red
3. 二胡独奏: 赛马  
Erhu Solo: Horse Racing
4. 舞蹈 纤夫的爱  
Han Dance: The Love of Boat Trackers
5. 二重唱: 我和我的祖国  
My motherland and I
6. 舞蹈: 花韵  
Han Dance: Spring Blooms

7:30-10:00pm      **Dance Party & Karaoke**  
-On-site Professional DJ  
-Line Dancing Led by ACP Dance Club



## Biographies for Speakers and Panelists

Alphabetical order based on the last name



### Chang Bai, PhD

Dr. Bai joined Pharmaron, Inc. in 2008 and established its Biology Department. Pharmaron is a premier R&D provider for the pharmaceutical industry, with over 1200 employees with operation both in the US and Beijing, China. Dr. Bai is currently Vice President of Biology at Pharmaron. His responsibilities include strategic development and technique operation for this area and in vitro ADMET. With the establishment of his Department and the acquisition of Bridge Laboratories China, Pharmaron becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. Prior to joining Pharmaron, he spent 12 years at Merck and Company, Inc., West Point, Pennsylvania. His responsibilities were drug discovery programs through biology and pharmacology studies, ranging from target ID/validation, assay development and compound profiling for MedChem and HTS campaigns to development of biomarker assays for in vivo models. He made critical contributions to the initiation of three lead OP programs and the identification of four candidates, with three reached clinical trials. Dr. Bai is an author of publications and meeting presentations that include highly cited articles in Cell, G&D, Nature, EMBO J, MCB, JBC, PNAS, and J. Med Chem. He received his Ph.D. with Dr. Stephen J. Elledge, at Baylor College of Medicine, and did postdoctoral fellowship with Dr. C. Thomas Caskey. He also served as a member of the Executive Council of SAPA (2006-2007, 2008-2009), SAPA-GP (2005-2010), and Oversea EC of SAPA-GP (2010-present).



### Ruiping Dong, PhD, MD

Dr. Dong is currently Senior Vice President, Head of emerging market R&D at Merck, Co. after serving as the Head of R&D Japan & China at BMS. Dr. Dong joined BMS in 2004 and served as VP of R&D Japan and various leadership roles with increased responsibilities in Asia-Pacific region. Prior to that, Dr. Dong was with AstraZeneca as medical advisor, product team lead, Head of clinical oncology. Before joining industry, he was a research fellow at Dana-Farber Cancer Institute, Harvard Medical School. He obtained his MD degree in Jiangxi Medical School in China, and PhD degree in Kyushu University of Medical School in Japan.



## Charles Q. Huang,

Charles Huang joined Sundia MediTech Company, Ltd., Shanghai, China ([www.sundia.com](http://www.sundia.com)) in March 2008. Sundia is a top Chinese CRO that provides fully-integrated drug discovery and development services to its worldwide clients. Charles is currently Vice President of Business Development who is responsible for all US and Canadian markets. Prior to Sundia, Charles served as president of Amnova, a pharmaceutical consultant firm in US. He worked for 15 year as medicinal chemist at Neurocrine Bioscience Inc (NBI), Johnson & Johnson and Amylin, including 4-year part-time experience on CRO project management and new market BD for advanced clinic candidate. During his tenure at NBI, Charles made significant contributions to CRF1, CRF-BP, and Insomnia projects, all resulting major collaborations with Johnson and Johnson, Eli Lilly and Pfizer. He is co-author for 22 publications, 10 presentations and 12 US patents. Charles graduated with BS in Polymer Chemistry from University of Science and Technology of China (USTC) in 1989, and obtained his MS in organic chemistry at California State University at Northridge. Besides his science and business career in drug discovery, Charles founded a non-profit 501c3 charitable organization in 2004 where he served as President (2004-2008) and Chair of Board (2008-2010).VP of Business Development. Email: [chuang@sundia.com](mailto:chuang@sundia.com)

## B. Robert Huang, PhD, MBA,

Dr. Robert Huang is President of Abgent, managing the company's global business including world-wide marketing and sales. With over 20 years of experiences, Dr. Huang has had responsibilities in R&D, business development, marketing and sales, and strategy & corporate development in Pharmaceutical, Biotech, and life science tools industries. His roles include Senior Director of Strategy & Corporate Development at Applied Biosystems, Business Development Director at Upstate/Serologicals/Millipore, Head of Bio-NMR group at Tularik, Inc. (Now part of Amgen), and Post-Doctorial Scientist at Abbot Laboratories. Dr. Huang has a PhD in Biochemistry at the Ohio State University and an MBA at Johnson Graduate School of Management of Cornell University, and BS/MS in chemistry at Peking University. Email: [rhuang@abgent.com](mailto:rhuang@abgent.com)



## Jason (Gang) Jin, MD, PhD

Dr. Jason (Gang) Jin is the CEO and Co-founder of ShanghaiBio Corporation (SBC for CRO), and Co-Founder & Executive VP of Global Business of Shanghai Biochip Co. Ltd (SBC), a leading biotech in China with lab operations at Shanghai and global business office at New Jersey in U.S. Dr. Jin is also an adjunct professor at the Shanghai Institutes of Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), and School of Pharmacy, Fudan University. Dr. Jin has extensive scientific and management experience in drug discovery and development. He has successfully developed and managed over 100 of R&D collaborative projects in biology discovery, preclinical research, and clinical trials with top global pharmaceutical and biotech companies in the past five years. He was awarded as one of top 10 American-Chinese returnees by Business Week in 2008. Dr. Jin also got the top 10 American-Chinese Business Award in 2010 at US. Dr. Jin has held the former positions of Director of Genomics Lab at Purdue Pharma (USA), Director of Functional Genomics at Salk Institute (USA), Founder Director of National Engineering Center for Biochip at Shanghai (China), and radiologist at Shanghai Zhongshan Hospital (China). He received Ph.D. and Postdoctoral Fellow in biology from University of California, San Diego (USA), and medical degree from School of Medicine, Fudan University (Shanghai Medical University, China). Dr. Jin also attended the intensive MBA class in Rutgers University.



### **Lee X Kang, PhD, MBA**

Dr. Lee Kang is currently Director Asia Pacific Quality Operations of the Perrigo Company (Stock Symbol: PRGO). He has held positions in Pharmaceutical R&D (both API and finished products), Regulatory Affairs, and Quality Assurance. Dr. Kang has 20 years of direct and managerial experiences in various CMC (Chemistry Manufacturing, and Controls) functions to support global clinical trials and market launches. Dr. Kang has worked in Bristol-Myers Squibb, Wyeth (now Pfizer), and Sanofi Aventis Pharmaceutical Companies in various CMC roles with increasing responsibilities. He has been an adjunct visiting professor in School of Pharmacy, State University of New York at Buffalo, New York. Dr. Kang received his Ph.D. from the Virginia Polytechnic Institute and State University, Blacksburg, Virginia, and MBA from the State University of New York at Buffalo, Buffalo, New York. His full profile can be viewed on LinkedIn professional network.

### **Song Li, PhD**

Dr. Li is the founder and President of Frontage Laboratories, Inc. Dr. Li received his Ph.D. in Analytical Chemistry from McGill University, Montreal, Canada, in 1992, and did two years post-doctoral research in Pharmacokinetics at the Oncology Department, Medical School of McGill University. Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth, and leads numerous projects related to the development of pharmaceutical products. Dr. Li has more than 15 years of pharmaceutical industry experience, and has more than twenty (20) scientific publications covering topics in chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. In 2002, Dr. Li founded Frontage Laboratories, Inc to provide integrated services to pharmaceutical companies all over the world. Currently, Frontage Laboratories has more than 160 employees in US and more than 60 employees in China, and provide services in bioanalytical, immunoassay, biomarker testing, formulation development and clinical product manufacturing, and clinical studies. For last four years, Frontage has been the winner of Philadelphia 100, one of the 100 fast growing companies in Great Philadelphia area.



### **Peter Peizhi Luo, Ph.D.**

Dr. Peter Luo is a serial entrepreneur with proven track record in technology innovation and product development in biotechnology and biopharmaceutical industry. He is the founder and chairman of Adagene, a biopharmaceutical company dedicated to the development of innovative technology and product. Prior to founding Adagene, Peter served as the Director of Biologics at Merck & Co., Inc. and Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co. Inc. from 2006 to 2010. Peter headed the team in designing and building Merck/Abmaxis industry-scale antibody libraries based on Abmaxis technology. He championed the use of Merck/Abmaxis antibody libraries as the discovery engine for Merck novel biologics. Prior to the acquisition of Abmaxis by Merck in May 2006, Peter was the Co-founder, Chief Technology Officer, President and Director of Abmaxis Inc. He is the core inventors of Abmaxis technology and led its technical development and collaboration with its corporate partners. He played a key role in shaping

Abmaxis technical and commercial strategies and in building its management and scientific advisory teams. He also actively participated in its fund-raising with corporate partners and venture capital firms and took part in the negotiation for M&A with investment bankers and corporate partners. Prior to founding Abmaxis in September 2000, Peter was the first lead scientist in Xencor and established its protein chemistry department. Peter has computationally designed and experimentally confirmed the first stabilized variants of GCSF with in vitro and in vivo efficacies. This designer protein was featured in Forbes "Better than Mother Nature", *an article on Biotech, Forbes, January 25, 1999*. Peter received a postdoctoral fellowship from the Arthritis Foundation in studying protein folding & design at Stanford University. He received his Ph.D. in physical and bioorganic chemistry in studying the structures of modified peptides and oligonucleotides from The University of Chicago, a MS degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and a B.S. degree in chemistry from Peking University.



### Steve Sun, PhD

Dr. Steve Sun is the President and CEO of GENEWIZ Inc, the company he co-founded in 1999. GENEWIZ is a contract research company that specializes in DNA sequencing, gene synthesis, molecular biology, genomics, and GLP/GLIA standard DNA services. GENEWIZ's global headquarters is located in New Jersey, with laboratory operations in New Jersey, California, Maryland, and Massachusetts in the US, and in Beijing and Suzhou in China. The mission of GENEWIZ is to contribute to the advancement of life sciences and technologies by making research more productive and cost efficient through scalable services. With works characterized by a high degree of speed, reliability, and competence, GENEWIZ serves thousands of researchers across the US and worldwide, and becomes the market leader in the DNA services. Independent marketing researching firm Frost & Sullivan selected GENEWIZ, Inc. as the recipient of the 2006 Growth Strategy Leadership Award, in recognition of its high quality services and unparalleled support in the North American DNA sequencing services markets. In 2010, Dr. Steve Sun, and Dr. Amy Liao, COO, co-founders of GENEWIZ, Inc. received the regional Ernst & Young Entrepreneur Of The Year Award. The Ernst & Young award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses, and is selected by an independent panel of judges. Dr. Sun serves as a member of the Scientific Advisor Board at Neogenix Oncology Inc, a cancer therapeutics and diagnostics company with operations in the states of New York and Maryland. Dr. Sun has been serving as a member of the Board of Directors at Frontage Laboratories since its founding in 2000. Dr. Sun serves as a member of the Innovation Sounding Board of Rutgers University's Center for Innovative Ventures of Emerging Technologies (CIVET). CIVET's mission is to encourage dialogue between academic researchers, their industrial counterparts, and entrepreneurs regarding technology commercialization. Dr. Sun obtained his Bachelor degree from Tsinghua University in Beijing, and his Ph.D. from Columbia University in New York City. His postdoctoral training was at the Rockefeller University in New York City.



### Peng Wang, PhD

Dr. Peng Wang joined Simcere, a leading Chinese pharmaceutical company (simcere.com; "SCR" @ NYSE), in 2009 as Chief Scientific Officer and Corporate Vice President. From April 2008 to May 2009, Peng was with WuXi PharmaTech ("WX" @ NYSE), a leading pharmaceutical CRO located in China, as Vice President of Discovery Biology. Prior to joining WuXi PharmaTech, Dr. Wang worked for Schering-Plough Research Institute in New Jersey, USA for 18 years,

where Dr. Wang made significant contributions to nomination of several development candidates as a Discovery Team Co-chair and/or biology group leader. Dr. Wang has published numerous papers as corresponding author in leading scientific journals such as Proc. Natl. Acad. Sci. USA, J. Biol. Chem., Blood, J. Immunol., Am. J. Respir. Crit. Care Med., Mol. Pharmacol., Biochem. J., etc. Dr. Wang received his Ph.D. in Biochemistry from the University of Tokyo.

### Wenyong Wang, PhD,

Dr. Wang joined Boenning & Scattergood in 2008 and currently is Vice President, Investment Banking, Boenning & Scattergood, Inc. Dr. Wang is a member of the Boenning Global Healthcare Investment Banking Practice. His responsibilities include scientific and financial evaluation of public and private biotechnology, pharmaceutical and medical device companies, fairness opinions, Merger & Acquisition licensing, private and public capital raising, and other financial and scientific advisory assignments. Dr. Wang's prior Investment Banking experience was with Janney Montgomery Scott in Philadelphia as a Vice President. With Janney, Dr. Wang and his team provided public and private clients throughout Asia, Europe and North America in advisory, capital raising, partnering and M&A. Previously, Dr. Wang worked on drug Research and Development at GlaxoSmithKline for more than six years. Prior to GSK, Dr. Wang conducted independent research on peptidomimetics at the University of Pennsylvania. Dr. Wang has a Ph.D. in Organic Chemistry from the University of Pennsylvania, a B.S. from Shandong University, and an M.B.A from Penn State. Dr. Wang holds series 7 and 63 and is registered representative with SEC and FINRA. E-Mail: [wwang@boenninginc.com](mailto:wwang@boenninginc.com)

### Patrick Wong, PhD

Dr. Wong, Professor of Pharmacology [emeritus], New York Medical College, Valhalla, NY USA. Currently, Director, Consultant Group, Qin Huang Dao Nobel Bio-Medical Industrial Park, Qing Huang Dao, Hebei, China. Dr. Wong was the founder of BioProst Pharmaceuticals, LLC, USA. Dr. Wong had over 30 years R/D experience in eicosanoids research and in clinical pharmacology on the discovery of new PG and LT molecules [publications 135 in peer reviewed journals]. During his academic career Dr. Wong had received research funding and supports from NIH, NIDR, American Heart Assoc., Phili Morris, etc. Dr. Wong was the founders of the NOBEL FORUM, an non-profit organization to promote the scientific understandings between Chinese scientists and western medical world. Since 1987, Dr. Wong had participated in the organization of over 10 International Conferences in USA, Hong Kong, Taiwan and China.



### Hua (Marlon) Zhong, PhD

Dr. Hua (Marlon) Zhong received his B.S. (1984) and M.S. (1987) in Chemistry from Zhejiang University in China, and his Ph.D. in Organic Chemistry from the Ohio State University in 1995. He joined J&J Pharmaceutical Research and Development, LLC (J&JPRD) as a postdoctoral fellow in 1995. After completing his postdoctoral tenure with Dr. Bruce E. Maryanoff in Medicinal Chemistry field, he continued his career in J&JPRD, as a process chemist and advanced through the ranks of the scientific ladder to Principal Scientist. During his 13 years tenure with J&J, Dr. Zhong has made significant contributions in the process development of various therapeutic agents and received an RWJPRI Achievement Award for process development of anti-influenza agent, RWJ-270201 (1999). After spent over 13 years in J&JPRD, Dr. Zhong joined Jiangyin PharmaAdvance, Inc. as CTO and vice President in 2008. His responsibilities include technical operation and strategic development of the company. Dr. Zhong made significant contributions to the growth of PharmaAdvance since he joined the company and was recently promoted to President of PharmaAdvance. Dr. Zhong is a member of American Chemical Society and Philadelphia Organic Chemists Club since 1995, and a member of SAPA since 1997. He also served as an executive council member for SAPA-GP (2006-2008) and for SAPA-HQ (2007-2008). Currently he is the oversea EC member for SAPA-GP.

# Sponsors



**Abgent** is the world largest primary antibody producer located in San Diego, CA and Shanghai/Suzhou, China. Our goal is to provide high quality products at low cost to support ground breaking scientific research across the globe. The company also provides a variety of related biological reagents and custom services for life science research, diagnostics and drug discovery. Our antibodies are widely used for Autophagy, Apoptosis, Stem Cells, Protein Modification, Gene Regulation, and many additional research areas. Our custom services include custom antibody, peptide, and protein expression, plus many more. Unlike most of our competitors, we serve our customers better by providing unique solutions to our clients to accelerate their research or drug discovery projects. With industry leading expertise gained from over nine years of experience, Abgent is at the forefront of providing such solutions needed by the scientific and pharmaceutical community.



**Sundia** is a leading CRO company located in the Zhangjiang Hightech Park of Shanghai, China. Sundia was founded by a group of veterans of the US biopharmaceutical industry. The founding team has received advanced doctorate degrees or training in US and each has got over 10-years of extensive working and/or management experience in the pharmaceutical & biotech industry. Sundia has always focused on customers' needs since we believe customer's success is our success. Sundia has provided "One Stop for All" CRO services for more than 70 companies in US, Europe and Japan to fit the increasing market demands for better and more efficient drug discovery & development process. Our integrated services include custom synthesis, medicinal chemistry, library production, hit generation, lead optimization, process chemistry R & D, API cGMP production, formulation development, PK in vitro & in vivo research & pre-clinical study. Sundia currently has over 120,000 sq. ft office/labs & 14 acres space of API/GMP manufacture facility and has employed around 500 scientists, of whom 16% are Ph.D.'s, 49% MS's, and 35% BS's.



**Qin Huang Dao BIO-MEDICAL INDUSTRIAL PARK (QHD Park):**

**QHD Park** is a newly developed industrial park with 130 sq. mile of land along the shore line of the Boar Sea. Phase 1 land development had completed with 500 acres of land for medical, pharmaceutical and biosciences companies. UNIVERSITY and education support included two major universities: YEN SHAN UNIVERSITY, NORTH CHINA

UNIVERSITY, also other college and nursing school. A new 500 beds GENERAL HOSPITAL is being constructed and will be finished in 2012. A NEW "NOBEL FORUM FUNCTIONAL MEDICINE INSTITUTE" is being built in the Park with R/D research program for Clinical Pharmacology and Functional Medicine. TRANSPORTATION for the Park is excellent with a new airport build in 2011. Rapid train from Beijing only takes 1 hr which will be in operation end of 2011. HOUSING is much cheaper than in Beijing. Exceptional ENVIRONMENTS with beautiful garden like working conditions. Good oxygen level, clean air like a Natural Oxygen Bar. The Park is seeking investments from US or Chinese Pharmaceutical and Biotech Companies. CONTACT: Patrick Wong, PhD., Huangpnj@gmail.com



Frontage offers a full range of pharmaceutical R&D services from their headquarters in Exton, Pennsylvania, near Philadelphia, and from a division in Shanghai, China. Founded in 2001 in New Jersey, Frontage has relocated its headquarters to Great Valley Industrial Park at western suburbs of Philadelphia, Pennsylvania. In recent years, Frontage has expanded its business rapidly including establishing its subsidiary in China, i.e. Frontage Laboratories (Shanghai) Co., Ltd in Shanghai and clinical research center in New Jersey. By utilizing its experienced resources, advanced R&D technologies and facilities as core competitiveness, Frontage specializes at solving complicated problems appearing in drug development required by leading pharmaceutical companies, improving their candidates to acquire FDA approval. Currently, Frontage Laboratories has more than 160 employees in US and more than 60 employees in China, and provide services in bioanalytical, immunoassay, biomarker testing, formulation development and clinical product manufacturing, and clinical studies. In recent years, Frontage has cooperated with many Chinese pharmaceutical companies on advancing their API and generic drugs to meet FDA guidelines and to enter into the global market. Frontage (Shanghai) has also collaborated with many Chinese pharmaceutical companies in areas such as GLP and cGMP certificate, ANDA filing, and generic drug development. Frontage (Shanghai) has experienced research staff, state-of-the-art lab equipments, and facilities that meet FDA's GMP and GCP requirements. Through its operation in China, Frontage (Shanghai) provides drug development services to Chinese pharmaceutical industry to file their pharmaceutical products in the US and Europe. Meanwhile, Frontage (Shanghai) can also help US pharmaceutical companies bring in their new products to China market. Frontage, as a rapid growth contract research organization in the US, with a ten-year successful history of its high quality GXP services, has established an international standard pharmaceutical products research and management system. Frontage has prioritized its developing strategy to China primarily, and already successfully helped many Chinese pharmaceutical companies develop a series of pharmaceutical products for global market. For more information, please visit the official Frontage websites at: [www.frontagelab.com](http://www.frontagelab.com) and [www.frontagelab.com.cn](http://www.frontagelab.com.cn)

# 永久保存 僅在此片刻停留

源自古埃及的神秘木乃伊，  
來自巴比倫尼亞的無價發現，  
前哥倫布時期的石刻碑，  
一切盡在眼前  
離費城華埠僅5分鐘距離

本次展覽將展出150多件珍貴文物，  
包括金器和錢幣、雕像、服飾、  
用具、個人用品、陪葬物品，  
甚至還包括保存完好的食物

2011年初，當“神秘絲路”來到  
費城賓大博物館的時候，  
這將可能是您看到這些稀世珍寶的  
最後一次機會，  
此後它們或許將永遠不再回來

歡迎預定團體票！  
詳情請撥打電話 (215)746-8183  
或登錄：[www.penn.museum](http://www.penn.museum)

美國東海岸唯一一次展覽  
SECRETS OF THE  
SILK ROAD  
神秘絲路大型展覽  
2011年2月5日到6月5日

Penn Museum  
賓大博物館  
UNIVERSITY OF PENNSYLVANIA MUSEUM  
of ARCHAEOLOGY and ANTHROPOLOGY  
3260 South Street / Philadelphia, PA

NBC 10  
PHILADELPHIA  
The Inquirer  
philly.com

## Media Partners

僑報

海華都市報  
Metro Chinese Weekly

多維時報

DUOWEI TIMES